Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Caspofungin
Drug ID BADD_D00376
Description Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
Indications and Usage For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
Marketing Status approved
ATC Code J02AX04
DrugBank ID DB00520
KEGG ID D07626
MeSH ID D000077336
PubChem ID 2826718
TTD Drug ID D00ZCN
NDC Product Code Not Available
UNII F0XDI6ZL63
Synonyms Caspofungin | Cancidas | MK 0991 | MK-0991 | MK0991 | Caspofungin MSD | L 743,872 | L-743,872 | L743,872 | L-743872 | L743872 | L 743872 | Caspofungin Acetate
Chemical Information
Molecular Formula C52H88N10O15
CAS Registry Number 162808-62-0
SMILES CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O) C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Venoocclusive liver disease12.02.09.039; 24.04.07.002; 09.01.06.0020.000224%
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Wheezing22.03.01.009--
White blood cell count decreased13.01.06.012--
White blood cell count increased13.01.06.013--Not Available
White blood cells urine positive13.13.02.004--Not Available
Infusion site erythema23.03.06.016; 12.07.05.009; 08.02.05.008--Not Available
Blood phosphorus decreased13.11.01.015--Not Available
Blood phosphorus increased13.11.01.016--Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000299%Not Available
Malignant neoplasm progression16.16.01.0050.000150%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Circumoral oedema10.01.05.013; 23.04.01.012--Not Available
Catheter site pain12.07.02.004; 08.02.02.004--Not Available
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.017--Not Available
Infusion site induration12.07.05.010; 08.02.05.009--Not Available
Infusion site pain12.07.05.002; 08.02.05.014--Not Available
Infusion site swelling12.07.05.003; 08.02.05.002--Not Available
Infusion site phlebitis24.12.03.002; 12.07.05.004; 08.02.05.003--Not Available
Infusion site pruritus12.07.05.005; 08.02.05.004; 23.03.12.006--Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000150%Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.007--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Infusion site rash23.03.13.018; 12.07.05.017; 08.02.05.017--Not Available
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages